Oral Sucrosomial Iron Is as Effective as Intravenous Ferric Carboxy-Maltose in Treating Anemia in Patients with Ulcerative Colitis
Anemia is a frequent complication of ulcerative colitis, and is frequently caused by iron deficiency. Oral iron supplementation displays high rates of gastrointestinal adverse effects. However, the formulation of sucrosomial iron (SI) has shown higher tolerability. We performed a prospective study t...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-02-01
|
| Series: | Nutrients |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6643/13/2/608 |
| _version_ | 1797396711594786816 |
|---|---|
| author | Lorenzo Bertani Domenico Tricò Federico Zanzi Giovanni Baiano Svizzero Francesca Coppini Nicola de Bortoli Massimo Bellini Luca Antonioli Corrado Blandizzi Santino Marchi |
| author_facet | Lorenzo Bertani Domenico Tricò Federico Zanzi Giovanni Baiano Svizzero Francesca Coppini Nicola de Bortoli Massimo Bellini Luca Antonioli Corrado Blandizzi Santino Marchi |
| author_sort | Lorenzo Bertani |
| collection | DOAJ |
| description | Anemia is a frequent complication of ulcerative colitis, and is frequently caused by iron deficiency. Oral iron supplementation displays high rates of gastrointestinal adverse effects. However, the formulation of sucrosomial iron (SI) has shown higher tolerability. We performed a prospective study to compare the effectiveness and tolerability of oral SI and intravenous ferric carboxy-maltose (FCM) in patients with ulcerative colitis in remission and mild-to-moderate anemia. Patients were randomized 1:1 to receive 60 mg/day for 8 weeks and then 30 mg/day for 4 weeks of oral SI or intravenous 1000 mg of FCM at baseline. Hemoglobin and serum levels of iron and ferritin were assessed after 4, 8, and 12 weeks from baseline. Hemoglobin and serum iron increased in both groups after 4 weeks of therapy, and remained stable during follow up, without significant treatment or treatment-by-time interactions (<i>p</i> = 0.25 and <i>p</i> = 0.46 for hemoglobin, respectively; <i>p</i> = 0.25 and <i>p</i> = 0.26 for iron, respectively). Serum ferritin did not increase over time during SI supplementation, while it increased in patients treated with FCM (treatment effect, <i>p</i> = 0.0004; treatment-by-time interaction effect, <i>p</i> = 0.0002). Overall, this study showed that SI and FCM displayed similar effectiveness and tolerability for treatment of mild-to-moderate anemia in patients with ulcerative colitis under remission. |
| first_indexed | 2024-03-09T00:55:25Z |
| format | Article |
| id | doaj.art-42fb1fd32c324ac7b74a647219438e88 |
| institution | Directory Open Access Journal |
| issn | 2072-6643 |
| language | English |
| last_indexed | 2024-03-09T00:55:25Z |
| publishDate | 2021-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Nutrients |
| spelling | doaj.art-42fb1fd32c324ac7b74a647219438e882023-12-11T16:55:55ZengMDPI AGNutrients2072-66432021-02-0113260810.3390/nu13020608Oral Sucrosomial Iron Is as Effective as Intravenous Ferric Carboxy-Maltose in Treating Anemia in Patients with Ulcerative ColitisLorenzo Bertani0Domenico Tricò1Federico Zanzi2Giovanni Baiano Svizzero3Francesca Coppini4Nicola de Bortoli5Massimo Bellini6Luca Antonioli7Corrado Blandizzi8Santino Marchi9Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56100 Pisa, ItalyDepartment of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, 56100 Pisa, ItalyDepartment of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56100 Pisa, ItalyDepartment of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56100 Pisa, ItalyDepartment of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56100 Pisa, ItalyDepartment of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56100 Pisa, ItalyDepartment of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56100 Pisa, ItalyDepartment of Clinical and Experimental Medicine, University of Pisa, 56100 Pisa, ItalyDepartment of Clinical and Experimental Medicine, University of Pisa, 56100 Pisa, ItalyDepartment of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56100 Pisa, ItalyAnemia is a frequent complication of ulcerative colitis, and is frequently caused by iron deficiency. Oral iron supplementation displays high rates of gastrointestinal adverse effects. However, the formulation of sucrosomial iron (SI) has shown higher tolerability. We performed a prospective study to compare the effectiveness and tolerability of oral SI and intravenous ferric carboxy-maltose (FCM) in patients with ulcerative colitis in remission and mild-to-moderate anemia. Patients were randomized 1:1 to receive 60 mg/day for 8 weeks and then 30 mg/day for 4 weeks of oral SI or intravenous 1000 mg of FCM at baseline. Hemoglobin and serum levels of iron and ferritin were assessed after 4, 8, and 12 weeks from baseline. Hemoglobin and serum iron increased in both groups after 4 weeks of therapy, and remained stable during follow up, without significant treatment or treatment-by-time interactions (<i>p</i> = 0.25 and <i>p</i> = 0.46 for hemoglobin, respectively; <i>p</i> = 0.25 and <i>p</i> = 0.26 for iron, respectively). Serum ferritin did not increase over time during SI supplementation, while it increased in patients treated with FCM (treatment effect, <i>p</i> = 0.0004; treatment-by-time interaction effect, <i>p</i> = 0.0002). Overall, this study showed that SI and FCM displayed similar effectiveness and tolerability for treatment of mild-to-moderate anemia in patients with ulcerative colitis under remission.https://www.mdpi.com/2072-6643/13/2/608anemiaironulcerative colitisclinical |
| spellingShingle | Lorenzo Bertani Domenico Tricò Federico Zanzi Giovanni Baiano Svizzero Francesca Coppini Nicola de Bortoli Massimo Bellini Luca Antonioli Corrado Blandizzi Santino Marchi Oral Sucrosomial Iron Is as Effective as Intravenous Ferric Carboxy-Maltose in Treating Anemia in Patients with Ulcerative Colitis Nutrients anemia iron ulcerative colitis clinical |
| title | Oral Sucrosomial Iron Is as Effective as Intravenous Ferric Carboxy-Maltose in Treating Anemia in Patients with Ulcerative Colitis |
| title_full | Oral Sucrosomial Iron Is as Effective as Intravenous Ferric Carboxy-Maltose in Treating Anemia in Patients with Ulcerative Colitis |
| title_fullStr | Oral Sucrosomial Iron Is as Effective as Intravenous Ferric Carboxy-Maltose in Treating Anemia in Patients with Ulcerative Colitis |
| title_full_unstemmed | Oral Sucrosomial Iron Is as Effective as Intravenous Ferric Carboxy-Maltose in Treating Anemia in Patients with Ulcerative Colitis |
| title_short | Oral Sucrosomial Iron Is as Effective as Intravenous Ferric Carboxy-Maltose in Treating Anemia in Patients with Ulcerative Colitis |
| title_sort | oral sucrosomial iron is as effective as intravenous ferric carboxy maltose in treating anemia in patients with ulcerative colitis |
| topic | anemia iron ulcerative colitis clinical |
| url | https://www.mdpi.com/2072-6643/13/2/608 |
| work_keys_str_mv | AT lorenzobertani oralsucrosomialironisaseffectiveasintravenousferriccarboxymaltoseintreatinganemiainpatientswithulcerativecolitis AT domenicotrico oralsucrosomialironisaseffectiveasintravenousferriccarboxymaltoseintreatinganemiainpatientswithulcerativecolitis AT federicozanzi oralsucrosomialironisaseffectiveasintravenousferriccarboxymaltoseintreatinganemiainpatientswithulcerativecolitis AT giovannibaianosvizzero oralsucrosomialironisaseffectiveasintravenousferriccarboxymaltoseintreatinganemiainpatientswithulcerativecolitis AT francescacoppini oralsucrosomialironisaseffectiveasintravenousferriccarboxymaltoseintreatinganemiainpatientswithulcerativecolitis AT nicoladebortoli oralsucrosomialironisaseffectiveasintravenousferriccarboxymaltoseintreatinganemiainpatientswithulcerativecolitis AT massimobellini oralsucrosomialironisaseffectiveasintravenousferriccarboxymaltoseintreatinganemiainpatientswithulcerativecolitis AT lucaantonioli oralsucrosomialironisaseffectiveasintravenousferriccarboxymaltoseintreatinganemiainpatientswithulcerativecolitis AT corradoblandizzi oralsucrosomialironisaseffectiveasintravenousferriccarboxymaltoseintreatinganemiainpatientswithulcerativecolitis AT santinomarchi oralsucrosomialironisaseffectiveasintravenousferriccarboxymaltoseintreatinganemiainpatientswithulcerativecolitis |